Elsevier

The Lancet

Volume 390, Issue 10103, 7–13 October 2017, Pages 1626-1628
The Lancet

Comment
Bevacizumab in cervical cancer: a step forward for survival

https://doi.org/10.1016/S0140-6736(17)31965-7Get rights and content

First page preview

First page preview
Click to open first page preview

References (10)

There are more references available in the full text version of this article.

Cited by (11)

  • Donor-acceptor structured photothermal COFs for enhanced starvation therapy

    2022, Chemical Engineering Journal
    Citation Excerpt :

    Cervical cancer is one of the most common female malignancies [1]. Recent years have witnessed its increasing incidence in much younger people[2]. Traditional treatment methods including chemotherapy, radiotherapy and resection often induced side toxicity, tissue damages, recrudesce and other problems[3,4].

  • Parents’ attitudes, beliefs and uptake of the school-based human papillomavirus (HPV) vaccination program in Jakarta, Indonesia – A quantitative study

    2021, Preventive Medicine Reports
    Citation Excerpt :

    In Indonesia, there were about 32,000 new cases in 2018 and 18,279 deaths (Bruni et al., 2018), making cervical cancer one of the most frequent cancers occurring in Indonesian females. Cervical cancer is curable if diagnosed and treated in the early stages of disease (Banerjee, 2017). In high income countries, the number of deaths caused by the disease has been reduced since cervical cancer screening programs have been available (Fisher and Brundage, 2009).

  • The prognostic landscape of tumor-infiltrating immune cells in cervical cancer

    2019, Biomedicine and Pharmacotherapy
    Citation Excerpt :

    However, the number of people utilizing these effective prevention strategies remains low in countries with a poor socioeconomic status [1], and there is an unmet clinical need for treatments for patients with advanced stages of cervical cancer [3]. This disease is incurable once it progresses to the metastatic or recurrent stage, and the prognosis is devastating, with an overall survival (OS) of approximately 12 months [4,5]. Therefore, new therapeutic approaches and novel biomarkers that provide prognostic information are urgently needed, especially for late-stage cervical cancer.

View all citing articles on Scopus
View full text